AKT1 and non-small cell lung carcinoma: Previous studies have shown that PI3K-AKT activation of EGFR signaling upregulates survivin expression, and persistent survivin expression is associated with erlotinib-resistance in EGFR mutation-positive NSCLC cells [42].